Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits ewing sarcoma cell growth

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1190-1203

  Grohar, Patrick J ^a   Segars, Laure E ^b   Yeung, Choh ^b   Pommier, Yves ^c   D'Incalci, Maurizio ^d   Mendoza, Arnulfo ^b   Helman, Lee J ^b  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^b Pediatric Oncology Branch   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FIRTECAN; IRINOTECAN; PROTEIN EWS FLI1; SMALL INTERFERING RNA; TRABECTEDIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WERNER SYNDROME PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; DIOXOLES; DISEASE MODELS, ANIMAL; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXODEOXYRIBONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROTO-ONCOGENE PROTEIN C-FLI-1; RECQ HELICASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; TETRAHYDROISOQUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895778881     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0901     Document Type: Article

References (53)

1. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
2. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007;254:1-10.
3. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 1997;17:495-7.
4. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009;106:5324-9.
5. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, et al. A molecular functionmapof Ewing's sarcoma. PLoSONE2009;4:e5415.
6. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulinlike growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7.
7. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL. EWS/ FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res 2012;10:1098-108.
8. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A, et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS ONE 2011;6:e19305.
9. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res 2009; 69:9047-55.
10. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G, et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 2008;68:7100-9.
11. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, et al. EWSFLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68: 2176-85.
12. Hu HM, Zielinska-Kwiatkowska A, Munro K, Wilcox J, Wu DY, Yang L, et al. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells. J Orthop Res 2008;26: 886-93.
13. Potikyan G, Savene RO, Gaulden JM, France KA, Zhou Z, Kleinerman ES, et al. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res 2007; 67:6675-84.
14. Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, Ban J, et al. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res 2010;70:4015-23.
15. Maksimenko A, Malvy C. Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Exp Opin Ther Targets 2005;9:825-30.
16. Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011;13:145-53.
17. Scotlandi K, Perdichizzi S, Manara MC, Serra M, Benini S, Cerisano V, et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002;8:3893-903.
18. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, et al. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 2005;27:1605-16.
19. Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 2008;19:3969-81.
20. Martinez N, Sanchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernandez I, et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005;4:814-23.
21. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7.
22. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000;97:6780-4.
23. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
24. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92: 583-8.
25. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, et al. Replication and homologous recombination repair regulate DNAdouble-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007;104:13062-7.
26. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9:2157-63.
27. Dileo P, Grosso F, Casanova M, Jimeno J, Marsoni S, Sanfilippo R, et al. Trabectedin in metastatic Ewing's family tumors patients progressing after standard chemotherapy. J Clin Oncol 2007;25: 10040.
28. Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, et al.Aphase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors: a Children's Oncology Group study. Clin Cancer Res 2005;11:672-7.
29. Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer 2012;48:579-85.
30. Pichierri P, Ammazzalorso F, Bignami M, Franchitto A. The Werner syndrome protein: linking the replication checkpoint response to genome stability. Aging 2011;3:311-8.
31. Muftuoglu M, Oshima J, von Kobbe C, Cheng WH, Leistritz DF, Bohr VA. The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet 2008;124:369-77.
32. Rossi ML, Ghosh AK, Bohr VA. Roles of Werner syndrome protein in protection of genome integrity. DNA Repair (Amst) 2010;9: 331-44.
33. Poot M, Gollahon KA, Rabinovitch PS. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet 1999;104:10-4.
34. Lebel M, Leder P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc Natl Acad Sci U S A 1998; 95:13097-102.
35. Pichierri P, Franchitto A, Mosesso P, Palitti F. Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage. Mutat Res 2000;456:45-57.
36. Boro A, Pretre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, et al. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. Int J Cancer 2012;131:2153-64.
37. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genomewide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010;29:2147-60.
38. Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma'ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 2010;26: 2438-44.
39. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 2011;103:962-78.
40. Dohjima T, Lee NS, Li H, Ohno T, Rossi JJ. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther 2003;7:811-6.
41. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
42. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
43. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 2005;65:4633-44.
44. Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 2004;64:1266-77.
45. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
46. Chou TC, Martin N. CompuSyn software for drug combinations and for general dose-effect analysis, and user's guide. Parasmus, NJ: ComboSyn, Inc. 2007
47. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002;277:26553-64.
48. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 2003;63:31-5.
49. Ueno M, Nonaka S, Yamazaki R, Deguchi N, Murai M. SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. Eur Urol 2002;42:390-7.
50. Sidorova JM, Li N, Folch A, Monnat RJ Jr. The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest. Cell Cycle 2008;7: 796-807.
51. Ammazzalorso F, Pirzio LM, Bignami M, Franchitto A, Pichierri P. ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery. EMBO J 2010;29:3156-69.
52. Houghton PJ, Cheshire PJ, Hallman JD 2nd, Lutz L, Friedman HS, Danks MK, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
53. Riccardi A, Meco D, Ubezio P, Mazzarella G, Marabese M, Faircloth GT, et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005; 16:811-5.